This study will evaluate the efficacy and safety of MabThera/Rituxan (rituximab) in treatment-naive patients with non-bulky follicular non-Hodgkin's lymphoma. The anticipated time on study treatment is 3 months.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
48
375 mg/m2 intravenously once a week for 4 weeks
Unnamed facility
Angers, France
Unnamed facility
Besançon, France
Unnamed facility
Bordeaux, France
Unnamed facility
Overall objective complete response rate
Time frame: Day 50
Overall objective partial response rate
Time frame: Day 50
Progression-free survival
Time frame: 7 years
Overall survival
Time frame: 7 years
Duration of response
Time frame: 7 years
Safety: Incidence of adverse events
Time frame: 7 years
Level of biological marker bcl2 in peripheral blood and bone marrow
Time frame: 7 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Clamart, France
Unnamed facility
Créteil, France
Unnamed facility
Le Mans, France
Unnamed facility
Lyon, France
Unnamed facility
Nantes, France
Unnamed facility
Nice, France
Unnamed facility
Paris, France
...and 6 more locations